Results 111 to 120 of about 2,751,693 (208)
Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate.
Selective inhibition of BCR/ABL expression by RNA interference has been demonstrated as an effective strategy in CML treatment and a reversal to imatinib resistance.
Yajuan Li +9 more
doaj +1 more source
Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA. Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.
Antonescu, C. R. +12 more
core +1 more source
Chronic myeloid leukemia (CML) is a clonal malignant hematopoietic disorder that arises in a hematopoietic stem cell. Its characteristic cytogenetic abnormality is an abnormal chromosome 22 called the Philadelphia (Ph) chromosome.
Meng Xiao +7 more
doaj +1 more source
Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment.
S. I. Kutsev +8 more
doaj
The role of P-glycoporotein in imatinib resistance [PDF]
H, Rumpold, A M, Wolf, D, Wolf
openaire +2 more sources
British Journal of Haematology, Volume 209, Issue 5, Page 2326-2330, November 2026.
Simone Claudiani +6 more
wiley +1 more source
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by the t(9; 22) and the related oncogene, BCR-ABL. Tyrosine kinase activity of fusion protein BCR-ABL is the main cause of CML.
Yalda Hekmatshoar +6 more
core +1 more source
Yusuf Baran,1 Guray Saydam21Department of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir, Turkey; 2Department of Hematology, School of Medicine, Ege University, Izmir, TurkeyAbstract: Chronic myeloid leukemia (CML) is a malignant ...
Saydam G, Baran Y
core
Figure S4. (A)The potential signaling pathway contributed to imatinib resistance in GIST. The green boxes and the solid arrows represented the previously reported signaling pathways related with imatinib resistance; the orange boxes and the dotted arrows
Tong Zhang (103827) +13 more
core +1 more source
Gastrointestinal stromal tumor (GIST) is mainly initialized by mutations in receptor tyrosine kinase genes KIT or PDGFRA. The development of imatinib, a small molecule inhibitor that targets these tyrosine kinase receptors, remarkably improved patient ...
Akçakaya, P,
core

